Apellis Pharmaceuticals Executive and Leadership Team

Jamie Hart, the Chief of Staff To the Chief Executive Officer at Apellis Pharmaceuticals, provides critical strategic support and operational oversight directly to the CEO. This executive manages key projects and initiatives, ensuring alignment with the company's overarching goals in developing novel therapeutic compounds for autoimmune diseases. The Chief of Staff To the Chief Executive Officer facilitates communication across departments, driving efficiency and strategic execution of the complement immunotherapy pipeline. By streamlining operations and enhancing decision-making processes, Jamie Hart directly supports Apellis's commitment to inhibiting the complement system at the C3 level. Hart's role is integral to advancing the company's mission from its Waltham, Massachusetts headquarters, ensuring swift progress in bringing life-changing treatments to patients.

Timothy Sullivan, the Chief Financial Officer at Apellis Pharmaceuticals, directs all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and capital allocation, the Chief Financial Officer ensures robust financial health to support the company's clinical-stage development of novel therapeutic compounds. This leadership role involves managing investor relations and securing funding necessary for advancing the pipeline of treatments targeting autoimmune diseases through complement immunotherapy. By optimizing financial resources, Timothy Sullivan directly contributes to the company's mission of inhibiting the complement system at the C3 level. Sullivan's financial acumen underpins Apellis's capacity to navigate the complexities of biopharmaceutical research and development, driving sustainable growth and market expansion from their Waltham, Massachusetts base.

Kristin Melaugh, the Chief of Staff, Commercial at Apellis Pharmaceuticals, spearheads strategic initiatives within the commercial division. This executive ensures seamless execution of go-to-market strategies for the company's therapeutic compounds, focusing on autoimmune disease treatments. The Chief of Staff, Commercial coordinates cross-functional efforts between sales, marketing, and market access teams, driving operational efficiency and market penetration. By aligning commercial activities with the broader company mission of complement immunotherapy, Kristin Melaugh enhances the reach and impact of Apellis's life-saving innovations. Melaugh's role is critical in translating scientific advancements into accessible treatments, supporting the company's objective to inhibit the complement system at the C3 level and improve patient lives globally.

Kelley Boucher, the Chief People Officer at Apellis Pharmaceuticals, directs all human capital strategies and organizational development initiatives. This executive cultivates a high-performance culture essential for driving innovation in the development of novel therapeutic compounds for autoimmune diseases. The Chief People Officer oversees talent acquisition, employee engagement, and leadership development, ensuring Apellis attracts and retains top talent in the biopharmaceutical sector. By fostering a supportive and dynamic work environment, Kelley Boucher directly contributes to the company's mission of advancing complement immunotherapy. Boucher's leadership ensures the workforce is equipped to meet the challenges of inhibiting the complement system at the C3 level, underpinning the company's success in delivering groundbreaking treatments.